BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33024084)

  • 21. Long-term outcomes of granulocyte colony-stimulating factor-combined conditioning in allogeneic hematopoietic stem cell transplantation from HLA-identical family donors for myeloid malignancies.
    Konuma T; Kato S; Ishii H; Oiwa-Monna M; Asano S; Tojo A; Takahashi S
    Leuk Res; 2015 Jun; 39(6):625-31. PubMed ID: 25888304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
    Kimby E; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2020 Dec; 99(12):2911-2925. PubMed ID: 33000361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network.
    Zappasodi P; Marbello L; Borlenghi E; Fumagalli M; Bernardi M; Fracchiolla N; Mancini V; Da Vià M; Ravano E; Cerqui E; Ferretti VV; Rocca B; Calvello C; Cazzola M; Castagnola C; Rossi G
    Ann Hematol; 2018 Nov; 97(11):2107-2115. PubMed ID: 30009341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: A National Population-Based Cohort Study.
    Østgård LSG; Lund JL; Nørgaard JM; Nørgaard M; Medeiros BC; Nielsen B; Nielsen OJ; Overgaard UM; Kallenbach M; Marcher CW; Riis AH; Sengeløv H
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):314-323. PubMed ID: 29051022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
    Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T
    Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.
    Pilorge S; Rigaudeau S; Rabian F; Sarkozy C; Taksin AL; Farhat H; Merabet F; Ghez S; Raggueneau V; Terré C; Garcia I; Renneville A; Preudhomme C; Castaigne S; Rousselot P
    Am J Hematol; 2014 Apr; 89(4):399-403. PubMed ID: 24375467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
    Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study.
    Sengsayadeth S; Gatwood KS; Boumendil A; Labopin M; Finke J; Ganser A; Stelljes M; Ehninger G; Beelen D; Niederwieser D; Blaise D; Dreger P; Mufti G; Chevallier P; Mailhol A; Gilleece MH; Gorin N; Esteve J; Ciceri F; Baron F; Schmid C; Giebel S; Mohty M; Savani BN; Nagler A
    Blood Adv; 2018 Aug; 2(16):2127-2135. PubMed ID: 30143527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351).
    Salhotra A; Aribi A; Ngo D; Zhang J; Sandhu K; Al-Malki M; Ali H; Koller P; Arslan S; Budde E; Khaled S; Dadwal S; Snyder DS; Artz A; Forman S; Nakamura R; Stein A; Marcucci G; Aldoss I; Pullarkat V
    Am J Hematol; 2021 Jun; 96(6):E196-E200. PubMed ID: 33719090
    [No Abstract]   [Full Text] [Related]  

  • 33. Sequential treatment combining cladribine-based re-induction, myeloablative allogeneic HSCT, and prophylactic donor lymphocyte infusion: a promising treatment for refractory acute myeloid leukemia.
    Xiao H; Li L; Pang Y; Wu Y; Jiang Z; Liu Z; Wu J; Xiao Y; Huang F; Liu Q; Zhang H; Luo Y; Huang H
    Ann Hematol; 2018 Dec; 97(12):2479-2490. PubMed ID: 30078144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?
    Derman BA; Larson RA
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101102. PubMed ID: 31779969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognosis and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
    Chen Q; Zhu XL; Zhao X; Liu X; Fu HX; Zhang YY; Chen YH; Mo XD; Han W; Chen H; Yan CH; Wang Y; Chang YJ; Xu LP; Huang XJ; Zhang XH
    Ann Hematol; 2021 Feb; 100(2):505-516. PubMed ID: 33389025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome of children with high-risk acute myeloid leukemia given autologous or allogeneic hematopoietic cell transplantation in the aieop AML-2002/01 study.
    Locatelli F; Masetti R; Rondelli R; Zecca M; Fagioli F; Rovelli A; Messina C; Lanino E; Bertaina A; Favre C; Giorgiani G; Ripaldi M; Ziino O; Palumbo G; Pillon M; Pession A; Rutella S; Prete A
    Bone Marrow Transplant; 2015 Feb; 50(2):181-8. PubMed ID: 25387094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study.
    Fang J; Zhang R; Wang H; Hong M; Wu Q; Nie D; You Y; Zhong Z; Li W; Hu Y; Xia L
    Leuk Res; 2016 Jul; 46():61-8. PubMed ID: 27131062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose cytarabine chemotherapy (≥4 g/m
    Nagahata Y; Kondo T; Ono Y; Hiramoto N; Kitano T; Hishizawa M; Yamashita K; Hashimoto H; Ishikawa T; Takaori-Kondo A
    Leuk Lymphoma; 2020 Dec; 61(13):3128-3136. PubMed ID: 32804016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical analysis of reduced conditioning intensity allo-HSCT treatment for relapsed ETO-positive AML].
    Guo Z; Chen HR; Liu XD; Lou JX; Yang K; Zhang Y; Chen P; He XP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1359-64. PubMed ID: 25338589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation.
    Parovichnikova EN; Loukianova IA; Troitskaya VV; Drokov MY; Lobaova TI; Kuzmina LA; Sokolov AN; Kokhno AV; Fidarova ZT; Baskhaeva GA; Gavrilina OA; Vasilyeva VA; Obukhova TN; Kuznetsova SA; Sudarikov AB; Dvirnik VN; Galtseva IV; Davidiva JO; Kulikov SM; Savchenko VG
    Ter Arkh; 2018 Aug; 90(7):14-22. PubMed ID: 30701918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.